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A B S T R A C T   
Oxaliplatin-induced neuropathy (OXAIN) is a major adverse effect of this antineoplastic drug, widely used in the 
treatment of colorectal cancer. Although its molecular mechanisms remain poorly understood, recent evidence 
suggest that maladaptive neuroplasticity and oxidative stress may participate to the development of this neu-
ropathy. Given the role played on protein remodeling by ubiquitin–proteasome system (UPS) in response to 
oxidative stress and in neuropathic pain, we investigated whether oxaliplatin might cause alterations in the UPS- 
mediated degradation pathway, in order to identify new pharmacological tools useful in OXAIN. In a rat model of 
OXAIN (2.4 mg kg− 1 i.p., daily for 10 days), a significant increase in chymotrypsin-(β5) like activity of the 
constitutive proteasome 26S was observed in the thalamus (TH) and somatosensory cortex (SSCx). In addition, 
the selective up-regulation of β5 and LMP7 (β5i) subunit gene expression was assessed in the SSCx. Furthermore, 
this study revealed that oprozomib, a selective β5 subunit proteasome inhibitor, is able to normalize the spinal 
prodynorphin gene expression upregulation induced by oxaliplatin, as well as to revert mechanical allodynia and 
thermal hyperalgesia observed in oxaliplatin-treated rats. These results underline the relevant role of UPS in the 
OXAIN and suggest new pharmacological targets to counteract this severe adverse effect. 
This preclinical study reveals the involvement of the proteasome in the oxaliplatin-induced neuropathy and 
adds useful information to better understand the molecular mechanism underlying this pain condition. More-
over, although further evidence is required, these findings suggest that oprozomib could be a therapeutic option 
to counteract chemotherapy-induced neuropathy.   
1. Introduction 
Oxaliplatin-based chemotherapy is the standard first-line treatment 
option for stage III of metastatic colorectal cancer treatment [1–3]. 
Although oxaliplatin exhibits valuable anti-cancer properties, it induces 
a painful neuropathy (OXAIN, oxaliplatin-induced neuropathy) as a 
prominent adverse effect [4–7] which represents its major dose-limiting 
toxicity. 
Different molecular mechanisms participate in the development of 
OXAIN, such as P2X7R-Pannexin1 system activation [8], peroxisome 
alterations [9]; furthermore, the involvement of specific channels or 
receptors, Kv7, 5HT2C and α7 nAChR [10–12] has been also proposed. In 
particular, the latter seems to play a crucial role in the pathophysiology 
of OXAIN being drastically decreased both in the peripheral and central 
nervous system of oxaliplatin-treated animals. Selective α7 nAChR ag-
onists prevent receptor downregulation and reduce hypersensitivity. 
Interestingly, the pain relieving effect of α7 nAChR agonists parallels a 
spinal decrease of dynorphin A [13], an endogenous kappa opioid re-
ceptor agonist that strongly contributes to neuropathic pain [14,15]. 
Other cellular functions have been associated with the activation and 
sensitization of pain signaling in sensory neurons. Indeed, we reported 
that during OXAIN the level of oxidative stress markers increases in the 
systemic circulation, in the peripheral and central nervous system 
[16,17], and the activation of glial cells also occurs [18,19]. This 
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evidence agrees with the hypothesis that antineoplastic agents can in-
crease pain modulators and free radical production, to whom mamma-
lian nerves seem to be more susceptible [20,21]. In this view, the 
degradation of non-functional oxidized proteins is essential for the 
maintenance of antioxidant defense machinery [22–24] that seems 
compromised in OXAIN. 
The major proteolytic machinery responsible for the removal of 
oxidized proteins is represented by the Ubiquitin-Proteasome System 
(UPS) whose protein degradation process is tightly regulated through 
the action of three different enzymes (E1, ubiquitin activating-; E2, 
ubiquitin conjugating- and E3, ubiquitin ligase-enzyme). They act 
sequentially by adding ubiquitin molecules to the substrate via lysine 
48, thus tagging proteins for 26S proteasome degradation [25–27]. The 
core particle (20S - CP) of 26S constitutive proteasome consists of four 
heteroheptameric rings where the proteolytic subunits are located. 
Theβ1, β2 and β5 subunits are endowed with proteolytic activity, cutting 
different protein substrates with caspase-, trypsin- and chymotrypsin- 
like activity, respectively [28]. 
The contribution of UPS activity to central sensitization, hyper-
algesia, and allodynia phenomena has been proposed [29]. Moreover, 
other studies highlighted the anti-inflammatory and anti-nociceptive 
effects exhibited by the proteasome inhibitor MG132 in a rat model of 
rheumatoid arthritis [30], further underlining UPS as a crucial molec-
ular target to be considered in analgesic therapy [31]. 
Besides the constitutive proteasome ubiquitously expressed, other 
classes of proteasome exist. One of them is represented by the immu-
noproteasome which is primarily expressed in cells of hematopoietic 
origin or in non-hematopoietic cells exposed to inflammatory cytokines 
[32,33]. In the immunoproteasome, the LMP2 (or β1i), MECL-1 (or β2i) 
and LMP7 (or β5i) subunits replace β1, β2 and β5 activities of the 
constitutive proteasome, respectively [34,35]. The immunoproteasome 
expression can be induced by inflammatory conditions [36] and 
immunoproteasome inhibition can block cytokine production and 
attenuate arthritis progression [37]. 
On these bases, and aiming at identifying new pharmacological tools 
useful to control OXAIN, we sought to evaluate whether rats exposed to 
oxaliplatin exhibit alterations in the UPS-mediated degradation 
pathway. To address this question, we focused our attention at both 
spinal and supraspinal level analyzing separately the lumbar, thoracic 
and cervical portions of rat spinal cord and selected supraspinal regions 
involved in pain transmission and modulation. In particular, we 
analyzed the thalamus (TH) and the somatosensory cortex (SSCx), 
sequentially activated along the pathway conveying nociceptive infor-
mation. In addition, the periaqueductal gray (PAG) matter was also 
investigated as a strategic hub in the descending pain control system 
[38,39]. To evaluate and discern the contribution of the constitutive and 
immunoproteasome complexes to the cleavage activity alterations 
induced by repeated exposure to oxaliplatin, we evaluated the gene 
expression of β5 and LMP7 (or β5i) proteasome subunits in the supra-
spinal areas. 
As noted above, neuropathic pain appears to be reduced by the 
intrathecal administration of proteasome inhibitors [29]. At the same 
time, an increase of spinal dynorphin A peptide levels associated with 
neuropathic pain conditions, appears to be reduced by a proteasome 
inhibitor treatment [40]. For these reasons, we also investigated the 
gene expression of spinal prodynorphin in OXAIN-suffering rats as well 
as the behavioral and neurochemical effects of the new active second- 
generation proteasome inhibitor compound, oprozomib. 
2. Materials and methods 
2.1. Animals 
Sprague Dawley rats (220–250 g; Envigo, Varese, Italy) were used. 
Animals were housed in the Centro Stabulazione Animali da Laboratorio 
(CeSal, University of Florence), four rats were housed per cage (size 26 
× 41 cm2); animals were fed with a standard laboratory diet and tap 
water ad libitum and kept at 23 ± 1 ◦C with a 12 h light/dark cycle (light 
at 7 A.M.). All animal manipulations were carried out according to the 
Directive 2010/63/EU of the European Parliament and of the European 
Union council (22 September 2010) on the protection of animals used 
for scientific purposes. The ethical policy of the University of Florence 
complies with the Guide for the Care and Use of Laboratory Animals of 
the US National Institutes of Health (NIH Publication No. 85–23, revised 
1996; University of Florence assurance number: A5278-01). Formal 
approval to conduct the experiments described was obtained from the 
Italian Ministry of Health (No. 498/2017-PR) and from the Animal 
Subjects Review Board of the University of Florence. Experiments 
involving animals have been reported according to ARRIVE guidelines 
[41]. Five animals per group were utilized in each experiment. All ef-
forts were made to minimize animal suffering and to reduce the number 
of animals used. 
2.2. Oxaliplatin-induced neuropathic pain model and oprozomib 
administration 
Oxaliplatin (2.4 mg kg− 1; Carbosynth, Compton, UK) was injected 
intraperitoneally (i.p.) for 5 consecutive days every week for 2 weeks for 
a total of 10 injections (from day 1 to day 5 and from day 8 to day 12) 
[42,43]. Oxaliplatin was dissolved in a 5% glucose solution. Oprozomib 
(30–100 mg kg− 1), suspended in 1% carboxymethylcellulose sodium salt 
(CMC; Sigma-Aldrich, Milan, Italy) was acutely administered per os (p. 
o.) on day 15, at the end of oxaliplatin injection (day 15) when neu-
ropathy was well established. Control animals received an equivalent 
volume of vehicles. 
2.3. Assessment of mechanical hyperalgesia (Paw pressure test) 
The nociceptive threshold of rats was determined by an analgesim-
eter (Ugo Basile, Varese, Italy), according to the method described by 
Leighton et al. [44]. Briefly, a constantly increasing weight was applied 
to a small area of the dorsal surface of the hind paw using a blunt conical 
probe by a mechanical device. Mechanical weight (expressed in g) was 
increased until vocalization or withdrawal reflex occurred while rats 
were lightly restrained. An arbitrary cut-off value of 100 g was adopted. 
2.4. Assessment of thermal allodynia (cold plate test) 
Thermal allodynia was assessed using the cold-plate apparatus (Ugo 
Basile, Varese, Italy). With minimal animal-handler interaction, rats 
were taken from home-cages, and placed onto the cold surface main-
tained at a constant temperature of 4 ◦C ± 1 ◦C. Ambulation was 
restricted by a cylindrical Plexiglas chamber (diameter: 10 cm, height: 
15 cm), with open top. Pain-related behavior (paw lifting or licking) was 
observed, and the time (s of the first sign was recorded. The cut-off time 
latency was set at 30 s [10]. 
2.5. Assessment of mechanical allodynia (Von Frey test) 
Mechanical allodynia was measured with an electronic Von Frey hair 
unit (Ugo Basile, Varese, Italy) as described by Sakurai and colleagues 
[45]. Briefly, rats were placed in 20 × 20 cm plexiglas boxes equipped 
with a metallic screen-mesh floor, 20 cm above the bench. A habituation 
of 15 min was allowed before the test. The withdrawal threshold was 
evaluated by applying a force ranging from 0 to 50 g with a 0.2 g ac-
curacy. The punctuate stimulus was delivered to the mid-plantar area of 
each posterior paw from below the meshy floor through a plastic tip and 
the withdrawal threshold was automatically displayed on the screen. 
The paw sensitivity threshold was defined as the minimum pressure 
required to elicit a robust and immediate withdrawal reflex of the paw. 
Voluntary movements associated with locomotion were not taken as a 
withdrawal response. Stimuli were applied on each posterior paw with 
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an interval of 5 s. The measure was repeated five times and the final 
value was obtained by averaging the five measures. 
2.6. Assessment of motor coordination (Rota-rod test) 
The Rota-rod apparatus (Ugo Basile, Varese, Italy) consisted of a base 
platform and a rotating rod with a diameter of 6 cm and a non-slippery 
surface. The rod was placed at a height of 25 cm from the base. The rod, 
36 cm in length, was divided into 4 equal sections by 5 disks. Thus, up to 
4 rats were tested simultaneously on the apparatus, with a rod-rotating 
speed of 10 revolutions per minute. The integrity of motor coordination 
was assessed on the basis of the time the animals kept their balance on 
the rotating rod for a maximum of 10 min (600 s). After a maximum of 6 
falls from the rod, the test was suspended and the time elapsed was 
recorded [46]. 
2.7. Tissue collection 
On day 15, at the end of the last behavioural test, animals were 
sacrificed using a guillotine. Thalamus (TH), the somatosensory cortex 
(SSCx) the periaqueductal gray (PAG) and the spinal cord (dissected in 
lumbar, thoracic and cervical portions) were collected and immediately 
frozen in liquid nitrogen for further ex vivo analysis. 
2.8. Proteasome activity assay 
Rat tissue samples were homogenized in lysis buffer (150 mM NaCl, 
50 mM HEPES pH 7.5, 5 mM EDTA, 2 mM ATP, 1% Triton;Sigma- 
Aldrich, Milan, Italy) and centrifuged at 14,000×g at 4 ◦C for 15 min. 
Homogenates were aliquoted and kept at − 80 ◦C. Protein concentration 
was determined by using Pierce™ BCA protein assay kit (Thermo Sci-
entific Massachusetts, USA). 
The proteasome trypsin- and chymotrypsin-like activities were 
analyzed monitoring the cleavage of two fluorogenic substrates using 
25 μg of lysate proteins. The substrates benzyloxycarbonyl-Ala-Arg-Arg- 
7-amino-4-methylcoumarin (Z-ARR-AMC) and succinyl-Leu-Leu-Val- 
Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) (both purchased 
from Merck Millipore, Milan, Italy) were used according to the manu-
facturer’s instructions to measure trypsin- (β2) and chymotrypsin-like 
(β5) activities, respectively. The assay is based on the detection of the 
fluorophore 7-amino-4- methylcoumarin (AMC) after cleavage from the 
labeled substrates Z-ARR-AMC or LLVY-AMC. All samples were run in 
triplicate and added to the substrates, then incubated for 2 h at 37 ◦C. 
The free AMC fluorescence was quantified at 380 nm excitation and 460 
nm emission wavelengths using a plate reader fluorometer (GENios 
Tecan). According to the manufacturer’s instructions, an AMC standard 
curve was generated for reference by preparing a dilution series of AMC 
standard reagent in the concentration range of 0.04–12.5 μM and run in 
triplicate. The assay was validated by analyzing proteasome positive 
control incubated with the inhibitor lactacystin and two independent 
experiments were carried out for each analyzed tissue. 
Data are expressed as percentage of relative fluorescence (RFU) and 
are reported as mean ± SEM of five rats per group. 
2.9. RNA isolation and qRT-PCR 
Total RNA was isolated using the TRIZOL reagent (Life Technologies, 
USA) according to the method of Chomczynski and Sacchi [47] and its 
integrity was checked by 1% agarose gel electrophoresis. In brief, the 
amounts of RNA were determined by measuring optical densities and 
only RNA samples with an OD260/OD280 1.8 < ratio < 2 were used. 
Total RNA was reverse transcribed using GeneAmp RNA PCR kit 
(ThermoFisher Scientific, USA) in a final volume of 20 μl, according to 
manufacturer’s instructions. Quantitative real-time PCR was performed 
on a StepOne Real-Time PCR System (Life Technologies, USA) using 
TaqMan Gene Expression Master Mix (ThermoFisher Scientific, USA), to 
analyze β5 (Rn01488742_m1, FAM-MGB) and the LMP7 (or β5i) 
(Rn00589926_m1, FAM-MGB) proteasome subunits gene expression, 
expressed by the constitutive and immune- proteasome complexes 
respectively [48,49]. All samples were run in triplicate and were 
normalized to the endogenous reference gene glyceraldehyde- 3-phos-
phate dehydrogenase (GAPDH) (Rn01775763_g1, VIC-MGB). Primers 
and probe sequences used for TaqMan gene expression were purchased 
from ThermoFisher Scientific, USA. 
To analyze pDYN gene expression the SYBR Green PCR MasterMix 
was used (Life Technologies, USA). Each sample was run in triplicate 
and all data were normalized to GAPDH. The primers used for PCR 
amplification in SYBR Green PCR MasterMix were designed using 
Primer 3, and are here reported: GAPDH Forward 5′- AGA-
CAGCCGCATCTTCTTGT-3′; GAPDH Reverse 5′-CTTGCCGTGGGTA-
GAGTCAT-3′; pDYN Forward 5′-CCTGTCCTTGTG TTCCCTGT-3′; pDYN 
Reverse 5′- AGAGGCAGTCAGGGTGAGAA-3′. Relative abundance of 
each mRNA species was calculated by Delta–Delta Ct (ΔΔCt) method 
and converted to relative expression ratio (2− ΔΔCt) for statistical analysis 
[50]. Data are expressed as means ± SEM (each sample run in triplicate) 
and represented as fold change in mRNA levels. 
2.10. Statistical analysis 
All experimental results were expressed as mean ± SEM and data 
were analyzed by t-test or by one-way ANOVA followed by Bonferroni’s 
multiple comparison post hoc test, as appropriate. P values < 0.05 were 
considered statistically significant. Investigators were blind to all 
experimental procedures. Statistical analysis was performed using 
GraphPad Prism software package (v7 for Windows, GraphPad Soft-
ware, San Diego CA, USA, www.graphpad.com). 
3. Results 
3.1. Assessment of oxaliplatin-induced neuropathic signs 
Two weeks of oxaliplatin repeated administrations significantly 
decreased the pain threshold to non-noxious (allodynia-like) and 
noxious (hyperalgesia-like) stimuli, evaluated on day 15 (Fig. 1). The 
licking latency in response to a thermal non-noxious stimulus (cold plate 
test) decreased from 19.3 ± 0.7 s of the control group to 9.5 ± 1.1 s in 
oxaliplatin-treated rats (Fig. 1a). The withdrawal threshold to a me-
chanical non-noxious stimulus (von Frey test) was significantly reduced 
in oxaliplatin-treated group (13.1 ± 0.7 g) with respect to control (20.7 
± 1.2 g) (Fig. 1b). Similarly, the weight tolerated by the animals on the 
posterior paws (mechanical noxious stimulus, paw pressure test) 
decreased from 65.0 ± 0.5 g of control groups to 45.3 ± 1.0 g in 
oxaliplatin-treated animals (Fig. 1c). Moving to the evaluation of oxa-
liplatin impact on motor coordination and physical endurance, the 
Rotarod test showed only a slight reduction of the time spent on the 
rotating rod with respect to the control group (Fig. 1d). 
3.2. Proteasome activities modulation in neuropathic rats 
3.2.1. Spinal cord. 
Intracellular trypsin- (β2) and chymotrypsin- (β5) like activities of 
the constitutive proteasome were assessed after oxaliplatin treatment in 
three different portions of spinal cord. Results indicated that oxaliplatin- 
treated rats did not show significant alteration at β2 subunit activity 
level in the three different portions of spinal cord examined (lumbar 
91.44 ± 2.82 vs 100.00 ± 2.76; thoracic: 91.58 ± 3.78 vs 100.00 ± 2.41; 
cervical: 100.25 ± 3.49 vs 100.00 ± 1.68, n.s.) (Fig. 2a, b and c). 
Similarly, the analysis of the β5 subunit activity did not show 
changes in the spinal cord of OXAIN-suffering rats (lumbar 95.93 ± 2.12 
vs 100.00 ± 1.57; thoracic: 93.65 ± 6.96 vs 100.00 ± 3.28; cervical: 
100.29 ± 5.75 vs 100.00 ± 5.38, n.s.) (Fig. 2d, e and f). 
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3.2.2. Supraspinal areas 
In the TH and in the SSCx, neuropathic rats exhibited no alteration of 
β2 subunit cleavage activity (TH: 105.78 ± 5.68 vs 100.00 ± 8.78; SSCx: 
106.13 ± 3.76 vs 100.00 ± 2.81, n.s.) (Fig. 3a and b). In contrast, the 
analysis of the β5 subunit showed a significant increase of the 
chymotrypsin-like activity in both TH and SSCx areas (TH: 115.10 ±
3.75 vs 100.00 ± 4.48, p < 0.05; SSCx: 137.61 ± 5.73 vs 100.00 ± 2.76, 
p < 0.001) (Fig. 3d and e). The analysis of β2 and β5 subunit cleavage 
activities showed no alteration in the PAG of oxaliplatin-treated rats 
compared to controls (β2 activity: 108.27 ± 5.39 vs 100.00 ± 4.85; β5 
activity: 93.93 ± 9.73 vs 100.00 ± 8.01, n.s.) (Fig. 3c and f). 
3.3. Gene expression analysis of β5 and LMP7 (or β5i) proteasome 
subunits 
Since the chymotrypsin-like activity assay does not allow to 
discriminate between the constitutive and immunoproteasome activa-
tion and based on the proteasome activity alterations detected in the TH 
and SSCx, we further evaluated the gene expression analysis of β5 and 
LMP7 proteasome subunits in the supraspinal areas. 
Oxaliplatin treatment induced a significant gene expression increase 
of β5 and LMP7 proteasome subunits in the SSCx (β5 mRNA levels: 1.78 
± 0.08 vs 1.00 ± 0.08, p < 0.001; LMP7 (or β5i) mRNA levels: 1.32 ±
0.09 vs 1.00 ± 0.06, p < 0.05) (Fig. 4c and d), which is more pronounced 
for the constitutive β5 subunit. On the contrary, gene expression analysis 
conducted in the TH did not show significant alterations in the gene 
codifying for both β5 and LMP7 proteasome subunits (β5 mRNA levels: 
1.07 ± 0.04 vs 1.00 ± 0.07; LMP7 (or β5i) mRNA levels: 1.03 ± 0.06 vs 
1.00 ± 0.15, n.s.) (Fig. 4a and b). 
3.4. Acute oprozomib abolishes oxaliplatin-induced increase of spinal 
prodynorphin gene expression 
Results indicated that oxaliplatin-treated rats exhibit significant al-
terations in spinal pDYN gene expression. In fact, in all the three 
different portions of spinal cord examined, a significant increase in 
pDYN mRNA levels was ascertained (cervical: 1.44 ± 0.08 vs 0.96 ±
0.14, p < 0.05; thoracic: 2.42 ± 0.19 vs 1.01 ± 0.09, p < 0.001; lumbar 
1.69 ± 0.12 vs 1.01 ± 0.09, p < 0.001; in oxaliplatin- or vehicle-treated 
groups, respectively) (Fig. 5a, b and c). 
Differently, pDYN mRNA levels measured in a separate group of 
oxaliplatin-exposed rats that were acutely treated with 30 mg kg− 1 i.p. 
of the proteasome inhibitor oprozomib on day 15 were significantly 
reduced compared with oxaliplatin-exposed animals in all spinal cord 
segments (cervical: 0.53 ± 0.12 vs 1.44 ± 0.08, p < 0.001; thoracic: 
0.48 ± 0.14 vs 2.42 ± 0.18, p < 0.001; lumbar 0,60 ± 0.07 vs 1.69 ±
0.12, p < 0.001; in oxaliplatin-oprozomib or oxaliplatin-vehicle treated 
groups, respectively) (Fig. 5a, b and c). 
3.5. Acute oprozomib administration reverts oxaliplatin-induced 
hyperalgesia 
Oprozomib was tested on day 15 of oxaliplatin protocol. After a 
single p.o. administration, oprozomib exerted an anti-hypersensitivity 
effect in a dose-dependent manner as depicted in Fig. 6. In particular, 
oprozomib 100 mg kg− 1, completely counteracted the thermal allodynia 
30 min after treatment, lasting up to 60 min. The lower dose (30 mg 
kg− 1) significantly increased the licking latency time between 30 min 
and 60 min (Cold plate test, Fig. 6a). Comparable results were obtained 
with the von Frey test, the response to a non-noxious mechanical 
Fig. 1. Behavioral measurements. Pain: non-noxious stimuli. (a) The response to a thermal stimulus was evaluated by the cold plate test measuring the latency (s) to 
pain-related behaviors (licking or lifting of the paw); (b) The von Frey test was used to measure the pain threshold as a response to a mechanical stimulus. Pain: 
noxious stimulus: (c) the paw pressure test was used to measure the sensitivity to a mechanical stimulus. Motor coordination. (d) The integrity of the animals’ motor 
coordination was assessed using the Rota rod apparatus measuring the time spent to keep their balance. Animals were daily treated with 2.4 mg kg− 1 oxaliplatin 
intraperitoneally (i.p.), over two weeks for a total of 10 injections. Behavioral evaluations were performed on day 15 when neuropathy was well established. Control 
animals were treated with vehicle. Each value represents the mean ± SEM of five rats per group. Statistical analysis is one-way ANOVA followed by Bonferroni’s post- 
hoc comparison test. **p < 0.01 vs vehicle group. 
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stimulus was significantly enhanced by oprozomib administration in a 
dose dependent-manner (Fig. 6b). The higher dose was effective from15 
min after administration up to 60 min while the dose of 30 mg kg− 1 was 
active from 30 min to 60 min. The anti-hyperalgesic effect of oprozomib 
against oxaliplatin neuropathy was evaluated by the Paw pressure test 
where the compound was able to revert the hypersensitivity to a noxious 
mechanical stimulus in a dose dependent-manner (Fig. 6c). 
4. Discussion 
Previous research provided robust evidence revealing the involve-
ment of several factors associated with the development and severity of 
OXAIN [51], such as the overexpression of organic cation transporter-2 
in neurons [52], the involvement of specific receptor systems [8,12,53] 
and also the dysfunction of different voltage-gated ion channels [54,55]. 
Fig. 2. β2 trypsin-like activity (left panels: a,b and c) and β5 chymotrypsin-like activity (right panels: d,e and f) of 20S Proteasome in the cervical, thoracic and 
lumbar portion of rat spinal cord after vehicle or oxaliplatin (2.4 mg kg− 1, i.p., daily for 10 days) treatment. Data are expressed as percentage of relative fluorescence 
(RFU) and are reported as mean ± SEM of five rats per group (n.s. p > 0.05 vs vehicle, t-test). 
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Among this plethora of mechanisms associated with oxaliplatin- 
induced neurotoxicity, it is worth to mention the contribution of UPS 
to the development and maintenance of OXAIN and, in this regard, the 
present study was aimed at exploring whether the proteasome degra-
dation machinery was involved in this neuropathic condition. Our major 
finding is that repeated exposure to oxaliplatin evokes alterations of the 
26S proteasome degradation machinery which are strictly dependent on 
the pain transmission – related region. Indeed, the analysis of β2 and β5 
enzymatic activities indicates that the repeated oxaliplatin exposure 
promotes a significant increase of intracellular chymotrypsin- (β5) like 
activity at supraspinal level only, in particular in the TH and SSCx, 
without changes in the three different portions of the spinal cord. On the 
other hand, the activity changes observed in the SSCx are accompained 
by alterations in gene expression, whereas in the TH only enzymatic 
activity is increased without gene expression activation. 
These results are consistent with evidence demonstrating that 
Fig. 3. β2 trypsin-like activity (left panels: a,b and c) and β5 chymotrypsin-like activity (right panels: d,e and f) of 20S Proteasome in the TH, SSCx and PAG of rat 
after vehicle or oxaliplatin (2.4 mg kg− 1, i.p., daily for 10 days) treatment. Data are expressed as percentage of relative fluorescence (RFU) and are reported as mean 
± SEM of five rats per group (n.s. p > 0.05; *p < 0.05; **p < 0.01 vs vehicle; t-test). 
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antineoplastic agents may increase the pro-inflammatory mediator 
signaling [20,21] likely through the activation of 26S proteasome 
complex [56]. In this view, the nuclear factor κ enhancer binding protein 
(NF-κB) transcription factor family activation requires the ubiquitina-
tion of inhibitory proteins of κB family (IκB) [57,58]. The 26S protea-
some proteolytic activity allows IκB post-translational modification and 
its degradation and the subsequent NF-κB translocation to the nucleus, 
where it regulates the expression of several genes including inflamma-
tory mediators such as cytokines and chemokines [59–61]. In other 
words, it is likely that repeated oxaliplatin administration promotes the 
increase of proteasome activity inducing the NF-κB transcription factor 
family activation as a consequence [62,63]. This hypothesis is supported 
by recent evidence from Wang and colleagues showing that different 
inhibition strategies of NF-κB p65 activation, such as siRNA targeting 
NF-κB p65, decreases thermal hyperalgesia induced by the antineo-
plastic agents [62]. The involvement of NF-κB in a variety of pain con-
ditions such as rheumatoid arthritis, migraine, and nerve injury has been 
thoroughly established [64–66]. In this regard, previous studies indicate 
the contribution of NF-κB activation in patients with acute spinal cord 
injury [67] and also in rat model of intervertebral disk herniation [68]. 
Moreover, sciatic nerve injury also promote supraspinal neuro- 
inflammation accompanied by high expression of NF-κB in rat brain 
[69]. 
In this frame, the inhibition of NF-κB activation through the use of 
proteasome inhibitor MG132 has been indicated as useful strategy to 
counteract the NF-κB induction of inflammatory pathways [70,71], and 
to modulate inflammatory pain in a rheumatoid arthritis rat model 
[30,72]. Therefore, the increase of proteasome activity reported in our 
experimental model corroborates the possibility that proteasome in-
hibitors could be effective in the treatment of painful states, including 
the peripheral neuropathy induced by oxaliplatin. Indeed, proteasome 
inhibitor administration seems to attenuate, prevent and revert pain 
behavioral signs in different neuropathic pain models [29,40]. 
The considerable increase of proteasome activity in the TH and SSCx 
and the selective up-regulation of β5 and LMP7 (or β5i) genes in the SSCx 
also indicates a peculiar activation of this supraspinal region which is 
mainly involved in the discriminative aspect of pain and sensory coding 
[73]. 
The protein degradation mediated by UPS is a crucial aspect in the 
synaptic plasticity regulation and, particularly, in the long-term synaptic 
modifications typical for chronic abnormal pain [31]. The main 
involvement of β5 isoforms, belonging to the constitutive and immune 
Fig. 4. Relative gene expression of β5 subunit of constitutive proteasome (left panels: a,c) and LMP7 (β5i) subunit of immunoproteasome (right panels: b,d) in the TH 
and SSCx of rat after Vehicle or Oxaliplatin (2.4 mgkg− 1i.p., daily for 10 days) treatment. Data represent 2− DDCt values calculated by DDCt method and are expressed 
as mean ± SEM of five rats per group (n.s. p > 0.05; *p < 0.05; ***p < 0.001 vs Vehicle; analyzed by t-test). 
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proteasomes respectively, suggests a relevant role played by these spe-
cific subunits in the oxidative stress processes induced by prolonged 
exposure to oxaliplatin. In this regard, β5 subunit represents the most 
important active site at the 20S-CP [74,75], and it also participates in 
Fig. 5. Relative gene expression of pDYN in the a) cervical, b) thoracic and c) 
lumbar portion of rat spinal cord. Data represent 2− DDCt values calculated by 
DDCt method and are expressed as mean ± SEM of five rats per group (*p <
0.05; ***p < 0.001 vs Vehicle; ###p < 0.001 vs Oxaliplatin-treated group; 
analyzed by One-way ANOVA followed by Bonferroni multiple compari-
sons test). 
Fig. 6. Behavioral measurements. Pain: non-noxious stimuli. (a) The response 
to a thermal stimulus was evaluated by the cold plate test measuring the latency 
(s) to pain-related behaviors (licking or lifting of the paw); (b) The von Frey test 
was used to measure the pain threshold as a response to a mechanical stimulus. 
Pain: noxious stimulus: (c) the paw pressure test was used to measure the 
sensitivity to a mechanical stimulus. Animals were daily treated with oxali-
platin 2.4 mg kg− 1 intraperitoneally (i.p.), oprozomib (30–100 mg kg− 1, p.o.) 
administration and behavioral evaluations were performed on day 15, before 
and 15, 30, 45, 60 and 90 min after oprozomib administration. Control animals 
were treated with vehicle. Each value represents the mean ± SEM of five rats 
per group. Statistical analysis is one-way ANOVA followed by Bonferroni’s post- 
hoc comparison. **p < 0.01 vs Vehicle + vehicle group; ^p < 0.05 and ^^p <
0.01 vs Oxaliplatin + vehicle group. 
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the increased response to oxidative stress carrying out a cytoprotective 
action [76,77]. Indeed, it has been demonstrated that the over-
expression of the β5 subunit is able to increase the proteasome activity 
and to promote cell survival following H2O2 exposure [76,77]. There-
fore, it is reasonable to speculate that proteasome activity increase and 
the selective β5 and LMP7 (or β5i) gene up regulation at supraspinal 
level could represent an adaptive response to the prolonged oxidative 
stress condition as that evoked by oxaliplatin also in the central nervous 
system [16,17]. This hypothesis is supported by the efficacy of antiox-
idant compounds in reducing the proteasome activation [78]. The same 
was reported by using the natural antioxidant melatonin [79]. 
Parallel to the increase of proteasome activity, we also observed a 
significant increase of pDYN gene expression in all three portions of the 
spinal cord. This observation confirms the involvement of the dynor-
phinergic system in the development of OXAIN as expected, given its 
role in several chronic pain conditions [15,80–82]. In this regard, Malan 
and colleagues associated the increase of dynorphin peptide level at 
spinal level, from a spatial and temporal point of view, to the appearance 
of mechanical allodynia [83]. 
An interesting hypothesis suggests that the increase of DYN release 
induced by oxaliplatin treatment may lead to its interaction with NMDA 
receptors [82] determining the presence of allodynia signs through the 
production of radical species and pro-inflammatory cytokines, which in 
turn contribute to the development of spinal neuronal damage [82,84]. 
Indeed, it is known the DYN ability to modulate nociception through its 
action on immune function [85]. In particular, the increase of dynorphin 
levels could be associated with the activation of a signaling cascade 
which, starting from the NMDA receptor, activates the transcription 
factor NF-κB and increase the expression of pro-inflammatory cytokines, 
nitric oxide and also DYN itself, as a consequence [84]. Therefore, the 
reduction of pDYN mRNA levels observed after oprozomib treatment 
could be associated to the ability of this second-generation proteasome 
inhibitor compound to inhibit NF-κB activation. 
Moreover, this latest finding agrees with previous studies showing 
the ability of proteasome inhibitors to down-regulate spinal DYN release 
[40]. 
The present, novel evidence of DYN involvement in the pathophys-
iology of OXAIN agrees with the parallelism existing between the α7 
nAChR-mediated neuropathic pain relief and DYN decrease. In a model 
of spinal nerve ligation, the activation of α7 nAChR alleviated neuro-
pathic pain behaviors and reduced DYN levels in the ipsilateral spinal 
cord [13]. In OXAIN, α7 nAChR expression is strongly downregulated in 
the nervous system, selective agonists are able to relieve pain by a glia- 
mediated mechanism and restore receptor levels [19]. A relationship 
between α7 nAChR downregulation and DYN increase may be hypoth-
esized in OXAIN mechanisms, strongly strengthening the role of treat-
ments able to normalize DYN. Furthermore, previous studies 
demonstrated a temporal change in the inflammatory response that 
accompanies OXAIN. In this view, it has been demonstrated that oxali-
platin treatment induces a marked increase of microglial density in the 
dorsal horns of the lumbar spinal cord after 7 days of treatment which 
decreases to control following 14 and 21 days. On the contrary, spinal 
astrocytes engagement is long lasting, suggesting a pivotal role of this 
cell population in the development of chronic pain as a part of central 
sensitization machinery [18]. 
Our data show a rapid DYN up-regulation at spinal level and a pro-
teasome activity increase at supraspinal level that could be related to the 
central sensitization. Nevertheless, the lack of proteasome alteration at 
spinal level represents an unexpected result which may suggest that this 
defense complex may be subjected to a temporal activation according to 
the area or cell population like microglia cells. 
In addition, our data show that although oxaliplatin induces a sig-
nificant increase of β5 subunit belonging to the constitutive proteasome, 
it is also able to promote the LMP7 (or β5i) subunit gene expression up- 
regulation. In this regard, some evidence demonstrated a prominent role 
of immunoproteasome in the adaptive immune response implicated in 
several biological and pathological processes. In fact, the immunopro-
teasome is known to be crucial in the degradation of damaged proteins 
generated by oxidative stress [86] and in inflammatory processes [87]. 
Therefore, given the role played by oxidative stress in peripheral neu-
ropathy induced by oxaliplatin [16], we tested the ability of an immune 
proteasome inhibitor to reduce OXAIN signs. In our study, a single 
oprozomib administration was able to counteract hyperalgesia and 
allodynia induced by oxaliplatin repeated injections that mimicks, in an 
animal model, the clinical adverse effects of this antineoplastic drug 
[88]. The results obtained on the efficacy of oprozomib could help to 
achieve the effect of oxaliplatin therapy reducing its toxicity. In 
particular, the use of immunoprotesome inhibitors has proved to be a 
potential useful approach especially in inflammatory and immune- 
related conditions. Indeed, it seems that the use of selective inhibitors 
for immuno subunits may result in a reduction of pro-inflammatory 
cytokines production [37,87]. 
Moreover, our data suggest for the first time that oprozomib is able to 
revert the increased prodynorphin gene expression occurring in OXAIN, 
thus indicating one of the possible molecular mechanisms underlying 
this pathological condition and identifying dynorphin as a possible 
target of immunoproteasome inhibitors, for new therapeutic ap-
proaches. We are also aware of the difficulty to directly associate 
oprozomib effects upon OXAIN to the UPS inhibitory action of the drug. 
This fact may represent a limit of our study and warrants further 
investigation. 
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